Thomas L. Clarke, Ph.D.
Principal Investigator

Thomas is originally from London, England, and studied Medical Science at the University of Exeter with a twelve-month research internship at Harvard Medical School. He then pursued a Ph.D. at the University of Birmingham in the laboratory of Dr. Clare Davies, working on understanding the importance of the arginine methyltransferase enzyme, PRMT5, in the DNA damage response (Clarke et al, Molecular Cell; 2017).

After his Ph.D., Thomas was awarded a competitive EMBO Postdoctoral Fellowship and joined the laboratory of Dr. Johnathan Whetstine at Massachusetts General Hospital and Harvard Medical School, where he worked on elucidating the importance of chromatin dynamics and histone modifications for the regulation of extra chromosomal DNA amplifications (Clarke et al, Cancer Discovery; 2020). After the completion of his EMBO fellowship, Thomas joined the laboratory of Dr. Raul Mostoslavsky, Scientific Director of the Massachusetts General Hospital Cancer Center, to bridge his interests in chromatin dynamics, DNA damage repair and genome stability maintenance. Funded by fellowships from the Charles King Trust and Massachusetts General Hospital Fund for Medical Discovery, Thomas has been working to identify and characterize novel chromatin factors involved in DNA damage repair, linking these factors to the pathology of several cancers and human developmental syndromes (Clarke et al, in revision).

In January 2024, funded by a National Institutes of Health K99/R00 career development award, Thomas joined the faculty at Boston University School of Medicine as an Assistant Professor to start his independent research laboratory.